




Started in 2021, mo:re is a biotechnology start-up developing the micro-lab for standardising and scaling 3D cell culture methods in pre-clinical research. Our modular benchtop robot automates manufacturing and characterisation to remove the main bottleneck in drug discovery.

Facts

Stage: Pre-Seed

Industry: Medical Biotechnology

Current Status: Working prototype; Pilot studies iPSC differentiation, breast cancer spheroids; Raising pre-seed to expand team.



Challenge

Animal models are the main bottleneck in the drug discovery

State-of-the-art (3D) cell models offer an economical and conclusive addition but cannot be established due to a lack of throughput & standardisation.

in vitro disease models

Hydrogels

Organs on a Chip

iPSC Differentiation

Spheroids

Organoids

Target Market 15,7% CAGR



- Cancer & Stem Cell Research
- Drug Development & Toxicology
- Tissue Engineering & Regenerative Medicine

How is our solution better?

The micro-lab is the first device to cover the planning, manufacturing, analysis and documentation of pre-clinical 3D cell studies. This allows for continuously optimising workflows to achieve an unmatched quality & reproducibility of 3D cell culture models, ultimately helping establish standard operating procedures.

Timeline

Preparing Pilots

Oct-Dec 2022

Hardware Development. 5+ LOI in Academia & Biotech

Product Validation

Jan-Jul 2023

Pre-clinical Data Generation. Improving User Experience

Go-to-Market

From Aug 2023

Expansion of Functionalities, Increasing Throughput, Establishing SOP



Lukas Gaats MS, MBA Founder & CEO **Application Business Development**



Founder & COO Automation Production



David Hackenberger MS, MBA Niklas Gollenstede MS, MBA Negar Shahmoradi MS Founder & CIO

Software



Founder & CTO Hardware



D-Prof. Dr. Dietmar W. Hutmacher Advisor (3D cell culture)



Prof. Dr.-Ing. Ralf Pörtner Advisor (EXIST)



















